Anti-tumor effect of tumor vaccine combined with metronomic chemotherapy on breast cancer in mice / 中国肿瘤临床

Objective:This study aimed to observe the synergistic effect of a new tumor vaccine combined with metronomic che-motherapy in vivo on breast cancer. This study was also conducted to investigate the mechanism of this combination. Methods:Balb/c mice inoculated with 4T1 mouse breast cancer cell were used as tumor models. High-mobility group nucleosome-binding protein 1 (HMGN1) gene was used to transfect 4T1 cell lines as cancer vaccines. After 4T1 cell was inoculated, the mice were randomized into four groups:normal saline (NS);metronomic gemcitabine (GEM) alone;cancer vaccine alone;and combination therapy group. Tumor growth and potential toxicities of these regimens were observed. The Foxp3 expression of regulatory T cells (Tregs) was detected by western blot and immunohistochemical staining. The microvessel density (MVD) of the tumor was also detected by immunohistochemi-cal staining. Results:The tumor volume of the mice was significantly lower in the combination group than in the MET group or cancer vaccine group (P<0.05). This result exhibited a higher significant difference than the tumor volume of the mice in the NS group (P<0.01). Foxp3 expression was significantly lower in the mice treated with GEM (combination or MET group). MVD was significantly lower in these two groups than in the cancer vaccine group or NS group (P<0.05). Furthermore, adverse reactions slightly occurred in each group. Conclusion: The combination of cancer vaccines and metronomic GEM is a very active and well-tolerated regimen for breast cancer in mice.

Effect of paclitaxel and gemcitabine on the expression of nucleosomal binding protein 1 in bladder cancer cell line T24 / 中华泌尿外科杂志

Objective To investigate the effect of paclitaxel and gemcitabine on the expression of nucleosomal binding protein 1(NSBP1) in bladder cancer cell line T24 and its significance. Methods Reverse transcription PCR(RT-PCR) and western blotting were used to detect the expression of NSBP1 in bladder cancer cell T24 treated by different concentration(10% ,40% ,80% IC50) of paclitaxel and gemcitabine for 48 hours. Results RT-PCR showed that relative optical density (OD) of NSBP1 in bladder cancer cell T24 treated by 0%, 10%,40% and 80% IC50 paclitaxel were 0.392 ±0.024, 0.227±0.037, 0.135±0. 063 and 0.091 ±0.017, respectively (P＜0.05). Relative OD of NSBP1 in bladder cancer cell T24 treated by 0%, 10%, 40% and 80% IC50 gemcitabine were 0.492±0.044, 0.262±0.031, 0.151±0.014 and 0.089±0.011, respectively. Western blotting showed that relative OD of NSBP1 in bladder cancer cell T24 treated by 0%, 10%,40% and 80% IC50 paclitaxel were 0.473±0.017, 0.252±0.041, 0.194±0.023 and 0.118±0.016, respectively. Relative OD of NSBP1 in bladder cancer cell T24 treated by 0, 10%, 40% and 80% IC50 gemcitabine were 0.581±0.014, 0.201±0.033, 0.135±0.021 and 0.114±0.011, respectively(P＜0.05). Conclusion Paclitaxel and gemcitabine can decrease the expression level of NSBP1 in bladder cancer cell line T24 both in mRNA and protein levels, so NSBP1 may be one of the targets of chemotherapy.